Download PDF
Thromb Haemost 2012; 108(04): 621-622
DOI: 10.1160/TH12-06-0440
Pro/Contra Article
Schattauer GmbH

Pro: “Antidote for new anticoagulants” – Specific target of inhibition requires a specific target for neutralisation

Vanessa Roldán
1   Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, University of Murcia, Murcia, Spain
,
Francisco Marín
2   Cardiology Unit, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Murcia, Spain
› Author Affiliations Financial support: This work was partially supported by PI11/1256 from ISCIII.
Further Information

Publication History

Received: 27 June 2012

Accepted after minor revision: 07 August 2012

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Ageno W, Gallus AS, Wittkowsky A. et al. American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-88S.
    CrossrefPubMed
  • 2 Keeling D, Baglin T, Tait C. et al. British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 2011; 154: 311-324.
    CrossrefPubMedGoogle Scholar
  • 3 Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008; 36-38.
    PubMedGoogle Scholar
  • 4 Levi M, Levy JH, Andersen HF. et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
    CrossrefPubMedGoogle Scholar
  • 5 Dentali F, Marchesi C, Pierfranceschi MG. et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-438.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl. 02) S5-S12.
    PubMedGoogle Scholar
  • 7 Phillips K, Ansell J. The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?. Thromb Haemost 2010; 103: 34-39.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Miesbach W, Seifried E. New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108: 625-632.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 09: 1705-1712.
    CrossrefPubMedGoogle Scholar
  • 10 Fukuda T, Honda Y, Kamisato C. et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107: 253-259.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of Rivaroxaban and Dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
    CrossrefPubMedGoogle Scholar
  • 12 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of Dabigatran and Rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 van Ryn J, Schurer J, Kink-Eiband M. et al. The successful reversal of Dabigatran induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2316.
    PubMedGoogle Scholar
  • 14 Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-3023.
    CrossrefPubMedGoogle Scholar
  • 15 Holbrook A, Schulman S, Witt DM. et al. American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e152S-84S.
    CrossrefPubMedGoogle Scholar
  • 16 Kaatz S, Kouides PA, Garcia DA. et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl. 01) S141-145.
    CrossrefPubMedGoogle Scholar
  • 17 Rodgers GM. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol. 2012 epub ahead of print..
    PubMedGoogle Scholar
  • 18 Gilmore R, Harmon S, Keane G. et al. Variation in anticoagulant composition regulates differential effects of prothrombin complex concentrates on thrombin generation. J Thromb Haemost 2009; 07: 2154-2156.
    CrossrefPubMedGoogle Scholar
  • 19 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Pengo V, Crippa L, Falanga A. et al. Italian Federation of Thrombosis Centers. Questions and answers on the use of Dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Marín F, Roldán V, Lip GY. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. Expert Opin Pharmacother 2012; 13: 1087-1090.
    CrossrefPubMedGoogle Scholar
  • 22 Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl. 01) S119-126.
    CrossrefPubMedGoogle Scholar